Longeveron (LGVN) Other financing activities (2020 - 2026)
Longeveron (LGVN) recorded quarterly Other financing activities of $379000.0 in Q1 2026, up 0.8% quarter-over-quarter from $376000.0 in Q4 2025, and up 11.47% on a YoY basis from $340000.0 in Q1 2025.
Longeveron (LGVN) Other financing activities (2020 - 2026) Analysis & Trends
Longeveron's Other financing activities history runs 5 years deep, the most recent figure standing at $379000.0 for Q1 2026.
- In Q1 2026, Other financing activities rose 11.47% year-over-year to $379000.0; the TTM figure through Mar 2026 stood at $9.4 million (up 259.15% YoY), while the FY2025 annual figure was $1.7 million, down 27.96% from the prior year.
- Other financing activities was $379000.0 for Q1 2026 at Longeveron, up from $376000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $8.2 million in Q2 2025 to a low of $340000.0 in Q1 2025.
- Historically, Other financing activities has averaged $1.6 million across 3 years, with a median of $390000.0 in 2024.
- The sharpest annual moves came in 2025 and 2026: Other financing activities sank 68.29% in 2025, then advanced 11.47% in 2026.
- A 3-year view of Other financing activities shows it stood at $390000.0 in 2024, then fell by 3.59% to $376000.0 in 2025, then increased by 0.8% to $379000.0 in 2026.
- The last three Other financing activities figures came in at $379000.0 (Q1 2026), $376000.0 (Q4 2025), and $448000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 379,000.00 |
| Mar 31, 2026 | 379,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Sep 30, 2025 | 448,000.00 |
| Sep 30, 2025 | 448,000.00 |
| Jun 30, 2025 | 8.16 Mn |
| Jun 30, 2025 | 8.16 Mn |
| Mar 31, 2025 | 340,000.00 |
| Mar 31, 2025 | 340,000.00 |
| Dec 31, 2024 | 390,000.00 |
| Dec 31, 2024 | 390,000.00 |
| Sep 30, 2024 | 1.41 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Dec 31, 2021 | 464,000.00 |
| Dec 31, 2021 | 464,000.00 |
| Sep 30, 2021 | 2.50 Mn |
| Sep 30, 2021 | 2.50 Mn |
| Jun 30, 2021 | 2.22 Mn |
| Jun 30, 2021 | 2.22 Mn |